ASSOCIATION OF CA-125 LEVELS WITH SEVERITY OF LIVER CIRRHOSIS AND ASCITES

Bansal Apoorva, Gupta Rohit, Prakash Archana, Jayala N, Sarika Arora

Abstract


Background: Elevated serum CA-125 levels have been used as pre-operative diagnostic and prognostic marker for
ovarian malignancy, which may increase in certain non-gynaecological disorders also. Many cases of liver cirrhosis may
be mis diagnosed as ovarian carcinoma due to combination of elevated CA125 and ascites.
Aim– To determine association between elevated serum levels of cancer antigen (CA) 125 and severity and prognosis of patients presenting with
liver diseases.
Material and Methods – A total of 80 patients were enrolled in this study. There were 34 patients of acute liver disease, 12 patients of
compensated cirrhosis and 34 patients of decompensated cirrhosis with ascites. Fasting LFT and CA -125 levels were measured in all patients.
Ultrasound abdomen was carried out to assess severity of ascites. Statistical analysis was carried out on SPSS. P-value less than 0.05 was taken as
significant
Results- The mean CA-125 levels in patients of acute liver disease (n=34) was 8.39±4.83 U/mL, in patients of compensated cirrhosis (n=12) was
9.74±3.39 U/mL and 286.28±219.71 U/mL in patients of decompensated cirrhosis with ascites (n=34). Mean CA-125 levels were significantly
higher in patients with ascites. A significant positive correlation was observed between serum CA-125 levels and severity of ascites ( p < 0.001).
Conclusions – Serum CA-125 levels have high predictive value for determining severity and progression of liver disease.


Keywords


CA =Cancer antigen, ALD= Acute liver disease, CLD= Chronic liver disease

Full Text:

PDF

References


Hussain SF, Camilleri P. Elevation of tumour marker CA-125 in serum & body fluids: interpret with caution. Indian J Med Res. 2007;125(1):10-12.

Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene. 2006; 373: 28–34.

Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68:1331-1337.

Lehtovirta P, Apter D, Stenman UH. Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol. 1990; 97:930- 933.

Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M. Clinical significance of serum CA125 values in patients with cancers of the digestive system. Am J Med Sci. 1986; 292: 30-34.

Singhal A, Lander E, Karachristos A, Daly E, Dowling P, Patel V etal. Elevation of CA-125 and CA 19-9 in patients with end-stage liver disease. Int J Biol Markers 2012; 27: e 147-e151.

Molina R, Filella X, Bruix J, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991; 37:1379-1383.

Zuckerman E, Lanir A, Sabo E, et al. CA-125 as a marker for detection and quantitation of ascites in liver cirrhosis [abstract]. Hepatology. 1995; 22(4, pt 2):163A.

Moore K P, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, etal. The Management of Ascites in Cirrhosis: Report on the Consensus Conference of the International Ascites Club. Hepatology. 2003; 38: 258-66.

Kim H, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol 2015; 31 (3): 184-191.

Wu EM, Wong LL, Hernandez BY, Ji JF, Jia W, Kwee SA, Kalathil S. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res 2018; 4: 66.

Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004;40:1426-33.

Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2014;20:6252-61.

Edula RGR , Muthukuru S, Moroianu S, Wang Y, etal. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol 2018; 6(3): 241–246.

Zuckerman E, Lanir A, Sabo E, et al. Cancer Antigen 125: A senstive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999;94:1613– 8.

Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE. The significance of CA-125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7: 199-203.

Deschenes M, Michel RP, Alpert E, Barkun JS,et al. Elevation of CA-125 is due to abdominal distension in liver transplant candidates. Transplantation 2001 ; 72 : 1519-22

15. Devarbhavi H, Kaese D, Williams A W, Rakela J, Klee GG, Kamath PS. Cancer Antigen 125 in Patients With Chronic Liver Disease. Mayo Clin Proc. 2002; 77:538-541

Collazos J, Genolla J, Ruibal A. CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scand J Clin Lab Invest 1992 May;52(3):201-206.

Zeimet AG, Offner FA, Marth C, et al. Modulation of CA 125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer-Res 1997;17: 3129-31


Refbacks

  • There are currently no refbacks.